These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25433666)

  • 1. Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment.
    McDonald CK; Martorell C; Ramgopal M; Laplante F; Fisher M; Post FA; Liu Y; Curley J; Abram ME; Custodio J; Graham H; Rhee MS; Szwarcberg J
    HIV Clin Trials; 2014; 15(6):269-73. PubMed ID: 25433666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor.
    Fisher M; McDonald C; Moyle G; Martorell C; Ramgopal M; Laplante F; Curley J; Graham H; Tran-Muchowski C; Liu Y; Rhee M; Szwarcberg J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19824. PubMed ID: 25397568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
    Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
    J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.
    Gallant J; Moyle G; Berenguer J; Shalit P; Cao H; Liu YP; Myers J; Rosenblatt L; Yang L; Szwarcberg J
    Curr HIV Res; 2017; 15(3):216-224. PubMed ID: 27774892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
    Putcharoen O; Do T; Avihingsanon A; Ruxrungtham K
    Drug Des Devel Ther; 2015; 9():5763-9. PubMed ID: 26566368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
    Yunquera-Romero L; Asensi-Díez R; Del Rio-Valencia JC; Muñoz-Castillo I; Castaño-Carracedo MA
    Rev Esp Quimioter; 2016 Dec; 29(6):308-317. PubMed ID: 27888600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.
    Arribas J; Rizzardini G; Arasteh K; Zurawski C; Dietz C; Pontani D; Garner W; Nguyen T
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19805. PubMed ID: 25397549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
    Deeks ED
    Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat.
    Marin RC; Streinu-Cercel A; Moleriu LC; Bungau SG
    Biomed Pharmacother; 2022 Jun; 150():113077. PubMed ID: 35658217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
    Post FA; Winston J; Andrade-Villanueva JF; Fisher M; Liu Y; Beraud C; Abram ME; Graham H; Rhee MS; Cheng AK; Szwarcberg J;
    J Acquir Immune Defic Syndr; 2015 Mar; 68(3):310-3. PubMed ID: 25469527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults.
    Tashima K; Crofoot G; Tomaka FL; Kakuda TN; Brochot A; Vanveggel S; Opsomer M; Garner W; Margot N; Custodio JM; Fordyce MW; Szwarcberg J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19772. PubMed ID: 25397516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atazanavir sulfate + cobicistat for the treatment of HIV infection.
    Antunes F
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):569-576. PubMed ID: 28443391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
    Majeed SR; West S; Ling KH; Das M; Kearney BP
    Antivir Ther; 2019; 24(8):557-566. PubMed ID: 31933482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents.
    Sevinsky H; Tao X; Wang R; Ravindran P; Sims K; Xu X; Jariwala N; Bertz R
    Antivir Ther; 2015; 20(5):493-500. PubMed ID: 25361436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cobicistat : a new opportunity in the treatment of HIV disease?
    Capetti A; Rizzardini G
    Expert Opin Pharmacother; 2014 Jun; 15(9):1289-98. PubMed ID: 24819446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
    Roberts O; Khoo S; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.
    German P; Liu HC; Szwarcberg J; Hepner M; Andrews J; Kearney BP; Mathias A
    J Acquir Immune Defic Syndr; 2012 Sep; 61(1):32-40. PubMed ID: 22732469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial.
    Brown K; Patterson-Browning B; Liu C; Patel M; Stewart L; Nettles RE
    Rev Recent Clin Trials; 2017; 12(3):174-181. PubMed ID: 28403798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.